β-Arrestin inhibition induces autophagy, apoptosis, G0/G1 cell cycle arrest in agonist-activated V2R receptor in breast cancer cells

Non-visual arrestins (beta-arrestins) are endocytic proteins that mediate agonist-activated GPCRs internalization and signaling pathways in an independent manner. The involvement of beta-arrestins in cancer invasion and metastasis is increasingly reported. So, it is hypothesized that inhibition of beta-arrestins may diminish the survival chances of cancer cells. This study aimed to evaluate the in vitro impact of inhibiting beta-arrestins on the autophagic and/or apoptotic responsiveness of breast cancer cells. We used Barbadin to selectively inhibit beta-Arr/AP2 interaction in AVP-stimulated V2R receptor of triple-negative breast cancer cells (MDA MB-231). Autophagy was assessed by the microtubule-associated protein 1 light chain 3-II (LC3II), apoptosis was measured by Annexin-V/PI staining and cell cycle distribution was investigated based upon the DNA content using flow cytometry. Barbadin reduced cell viability to 69.1% and increased the autophagy marker LC3II and its autophagic effect disappeared in cells transiently starved in Earle's balanced salt solution (EBSS). Also, Barbadin mildly enhanced the expression of P62 mRNA and arrested 63.7% of cells in G0/G1 phase. In parallel, the drug-induced apoptosis in 29.9% of cells (by AV/PI) and 27.8% of cells were trapped in sub-G1 phase. The apoptotic effect of Barbadin was enhanced when autophagy was inhibited by the PI3K inhibitor (Wortmannin). Conclusively, the data demonstrate the dual autophagic and apoptotic effects of beta-beta Arr/AP2 inhibition in triple-negative breast cancer cells. These observations nominate beta-Arrs as selective targets in breast cancer treatment.

Automated summary

The study demonstrates the dual autophagic and apoptotic effects of inhibiting beta-arrestins in triple-negative breast cancer cells. These findings suggest beta-arrestins as selective targets in breast cancer treatment.